Stocks · News reference
FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meetingFour AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.45) by 38.64 percent. This is a 40 percent increase over losses of $(0.45) per share
Read original at benzingaARMP stock jumps 10% as Armata Pharmaceuticals prepares its AP-SA02 multi-phage candidate for a pivotal Phase 3 trial in late 2026.
Read original at benzinga